Solventum Corporation

Solventum Corporation

SOLV·NYSE

$78.36

+2.5%
HealthcareMedical - Care Facilities

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

At a Glance

Live Snapshot
Market Cap$13.57B
EPS8.9400
P/E Ratio8.77
Earnings Date08/06/2026
17.76%
Return on Invested Capital
159%
3Y+62.0%
5Y-
10Y-
30.82%
Return on Equity
90%
3Y+169.0%
5Y-
10Y-
10.89%
Return on Assets
229%
3Y+10.0%
5Y-
10Y-
Solventum Corporation

Solventum Corporation Management Team

SOLV · NYSE
MK

Ms. Kate Dobbs

Chief Communications & Brand Officer

female
MB

Mr. Bryan C. Hanson

Chief Executive Officer & Director

Compensation

$10,370,481

Born 1967(Age 59)
male
MW

Mr. Wayde D. McMillan

Chief Financial Officer

Compensation

$1,557,992

Born 1970(Age 56)
male
MT

Ms. Tammy L. Gomez

Chief Human Resources Officer

Compensation

$1,119,093

Born 1973(Age 53)
female
MA

Ms. Amy Landucci

Chief Information & Digital Officer

Compensation

$2,319,204

Born 1976(Age 50)
female
MM

Ms. Marcela A. Kirberger

Chief Legal Affairs Officer & Corporate Secretary

Born 1968(Age 58)
female
MR

Ms. Rachel H. Ellingson

Chief Strategy & Corporate Development Officer

Born 1970(Age 56)
female
MJ

Mr. J. Christopher Barry

Executive Vice President & Group President of Medical Surgical

Compensation

$1,763,436

Born 1972(Age 54)
male
MA

Ms. Amy Wakeham

Senior Vice President of Investor Relations & External Finance Communications

female
MM

Ms. Mary T. Wilcox

Senior Vice President, Corporate Controller & Chief Accounting Officer

Born 1965(Age 61)
female
solv

Solventum Corporation Insider Positioning

SOLV · NYSE

During the last 12 months, insiders have purchased $100K and sold $646.36M worth of SOLV shares, resulting in $646.26M of net selling activity.

3 Months

Bought

1.5K

100.34K

Sold

0

0.00

Net Activity

+100K

+$100K

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

8.8M

646.36M

Net Activity

-646.4M

-$646.36M

Top Buyers

1
WAM

Wendell Amy Mcbride

Director

1.5K shares1 transactions

$100K

Top Sellers

1
3C

3M Co

10 Percent Owner

8.8M shares1 transactions

$646.36M

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $646.26M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$100K

Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.

Insider Participation

Balanced

1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.

SEC Filings

SOLV - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

March 27, 2026
December 31, 2025
2025
DEF 14A

DEF 14A 2024

N/A

March 21, 2025
December 31, 2024
2024
Showing 1 to 2 of 2 filings